Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Psoriatic Arthritis (Jul 2019)

Posted by Matt Breese on Jul 5, 2019

Find me on:

According to our recent payer coverage analysis for psoriatic arthritis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for psoriatic arthritis treatments shows that under the pharmacy benefit, about 74% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Psoriatic Arthritis_2Q2019Data snapshot as of Q2 2019

Trends: Manufacturers with franchises across indications often hold contracting power and improved positio, which is everything in this market. In terms of contracting, Humira is the product to beat, and Enbrel battles for the second place.

To read the full Reality Check on Psoriatic Arthritis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing